Innate Pharma Balance Sheet Health
Financial Health criteria checks 4/6
Innate Pharma has a total shareholder equity of €51.9M and total debt of €39.1M, which brings its debt-to-equity ratio to 75.3%. Its total assets and total liabilities are €184.2M and €132.3M respectively.
Key information
75.3%
Debt to equity ratio
€39.06m
Debt
| Interest coverage ratio | n/a |
| Cash | €92.46m |
| Equity | €51.90m |
| Total liabilities | €132.29m |
| Total assets | €184.19m |
Recent financial health updates
Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?
Dec 21
Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?
Jun 09Does Innate Pharma (EPA:IPH) Have A Healthy Balance Sheet?
Sep 27Is Innate Pharma (EPA:IPH) Weighed On By Its Debt Load?
Nov 11Is Innate Pharma (EPA:IPH) Using Debt Sensibly?
May 04Recent updates
Benign Growth For Innate Pharma S.A. (EPA:IPH) Underpins Its Share Price
May 21Innate Pharma S.A. (EPA:IPH) Annual Results: Here's What Analysts Are Forecasting For This Year
Mar 24Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?
Dec 21Analysts' Revenue Estimates For Innate Pharma S.A. (EPA:IPH) Are Surging Higher
Sep 30Some Innate Pharma S.A. (EPA:IPH) Analysts Just Made A Major Cut To Next Year's Estimates
Sep 16Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?
Jun 09News Flash: Analysts Just Made A Massive Upgrade To Their Innate Pharma S.A. (EPA:IPH) Forecasts
Mar 30Rainbows and Unicorns: Innate Pharma S.A. (EPA:IPH) Analysts Just Became A Lot More Optimistic
Dec 18Does Innate Pharma (EPA:IPH) Have A Healthy Balance Sheet?
Sep 27Innate Pharma S.A. (EPA:IPH) Analysts Are Reducing Their Forecasts For This Year
Aug 04Industry Analysts Just Made A Dazzling Upgrade To Their Innate Pharma S.A. (EPA:IPH) Revenue Forecasts
May 12Industry Analysts Just Made A Captivating Upgrade To Their Innate Pharma S.A. (EPA:IPH) Revenue Forecasts
Apr 13Time To Worry? Analysts Just Downgraded Their Innate Pharma S.A. (EPA:IPH) Outlook
Mar 26Is Innate Pharma (EPA:IPH) Weighed On By Its Debt Load?
Nov 11Revenue Downgrade: Here's What Analysts Forecast For Innate Pharma S.A. (EPA:IPH)
May 13Is Innate Pharma (EPA:IPH) Using Debt Sensibly?
May 04A Look At Innate Pharma's (EPA:IPH) Share Price Returns
Feb 26Financial Position Analysis
Short Term Liabilities: IPH's short term assets (€148.0M) exceed its short term liabilities (€39.6M).
Long Term Liabilities: IPH's short term assets (€148.0M) exceed its long term liabilities (€92.7M).
Debt to Equity History and Analysis
Debt Level: IPH has more cash than its total debt.
Reducing Debt: IPH's debt to equity ratio has increased from 1.5% to 75.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IPH has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if IPH has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.